Less Invasive Ventricular Enhancement™ (LIVE™)

  • Remodel Heart Failure
  • Regain Function
  • Renew Life

About Us

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

Less Invasive Ventricular Enhancement™ or LIVE™ is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC™ TransCatheter Ventricular Enhancement System is a safer and less invasive alternative compared to a ventricular assist device (VAD) or a heart transplant. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for multidisciplinary heart teams and their patients by its proven clinical improvements.

Our Management Team

Jim Dillon - President and Chief Executive Officer

President and Chief Executive Officer

William R. Abbott - Chief Financial Officer
Thasee Pillay - Chief Medical Officer
Lon S. Annest, M.D. - Vice President of Medical Affairs
Chris Wolff - Vice President of U.S. Sales
Pedro Marques - Vice President of EMEA
Noel Messenger - Vice President of Quality, Regulatory Affairs, and Clinical Affairs

Our Board of Directors

Steven Healy

Board Chairman, BioVentrix

Former General Manager, Global Spine, Zimmer Biomet

George Fazio
Jim Dillon
Mark Ravich
Mike Taglich
Raymond Cohen

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.

Our News

Contact Us

© 2021 BioVentrix. All Rights Reserved. Powered by MedTech Momentum
The Revivent TC™ trademark is a federally registered trademark owned by BioVentrix. Any unauthorized use is expressly prohibited.